| 2024-11-18 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting silence-therapeutics.com ↗
Results presented today showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks. |
| 2024-06-20 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) silence-therapeutics.com ↗
These data demonstrated a highly significant reduction from baseline in Lp(a) compared to placebo to 48 weeks (end of treatment and dosing period). |
| 2024-04-08 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) silence-therapeutics.com ↗
|
| 2024-03-13 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights silence-therapeutics.com ↗
That’s clearly bearing fruit today with the positive topline 36-week data we announced from the ongoing phase 2 study of zerlasiran in patients with high Lp(a). |
| 2024-03-13 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) silence-therapeutics.com ↗
|
| 2023-11-01 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease silence-therapeutics.com ↗
These data demonstrated a significant reduction from baseline in Lp(a) of up to 99% at 90 days following injection of repeated doses. |
| 2023-01-12 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates silence-therapeutics.com ↗
In the single dose study evaluating healthy volunteers with high Lp(a), participants who received SLN360 (300 mg and 600 mg doses) saw median maximal Lp(a) reductions of 96% and 98%, respectively. |
| 2022-11-05 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting silence-therapeutics.com ↗
In the top two SLN360 single dose groups (300 mg and 600 mg), median time-averaged Lp(a) reductions over 150 days exceeded 80%. |
| 2022-04-03 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a) silence-therapeutics.com ↗
The paper, authored by senior medical and scientific experts from both Silence and leading cardiology centers, showed that SLN360 reduced blood levels of Lp(a), a key genetic risk factor for heart disease, by up to 98% in healthy adults with elevated Lp(a). |
| 2022-04-03 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting silence-therapeutics.com ↗
|
| 2022-02-09 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a) silence-therapeutics.com ↗
|
| 2020-11-16 |
Silence Therapeutics GmbH |
Results Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020 silence-therapeutics.com ↗
|